On June 30 2023, PRAXIS PRECISION MEDICINES ($NASDAQ:PRAX) reported their second quarter fiscal year 2023 earnings results. Total revenue for the quarter had increased to USD 0.8 million, compared to the 0.0 million reported in the same quarter of the previous year. Net income also showed improvement from -60.2 million to -34.3 million.
On Wednesday, the stock of PRAXIS PRECISION MEDICINES opened at $1.0 and closed at $1.0, up by 0.4% from its previous closing price of $1.0. This increase in share price was in response to the strong second quarter earnings report released by the company for the fiscal year of 2023. The strong earnings report indicates that PRAXIS PRECISION MEDICINES is continuing to be a successful and profitable company despite the many challenges presented by a global pandemic. The company is focusing on cost-cutting measures and utilizing their technology to bring precision medicines to patients in need.
As the world continues to look for innovative solutions to healthcare, PRAXIS PRECISION MEDICINES is leading the way with its technology-driven approach. Overall, the strong second quarter earnings report from PRAXIS PRECISION MEDICINES is encouraging and suggests that the company is well-positioned to continue to succeed in the future. Investors are sure to keep a close eye on this stock as it continues to make progress in providing precision medicines to those in need. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for PRAX. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PRAX. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PRAX. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for PRAX are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have conducted a comprehensive analysis of PRAXIS PRECISION MEDICINES’s fundamentals. Our risk rating indicates that it is a medium risk investment in terms of financial and business aspects. If you are interested in learning more, you can register and view our detailed analysis. We have identified four potential risk warnings in the income sheet, balance sheet, cashflow statement, and financial journal. These warnings could indicate a lack of stability or security in the company’s operations. We recommend that you evaluate these warnings thoroughly before making an investment decision. Your security is our priority at GoodWhale, so we strive to provide you with up-to-date and accurate financial information for PRAXIS PRECISION MEDICINES. Keep in mind that no investment is without risk and we encourage you to do your own research before making any decisions. More…
Risk Rating Analysis
Star Chart Analysis
The company’s competitors include ARCA biopharma Inc, Gossamer Bio Inc, Freeline Therapeutics Holdings PLC.
ARCA biopharma Inc is a clinical-stage biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases. The company’s lead product candidate, Gencaro (bucindolol), is a beta blocker and mild vasodilator that is in Phase III clinical development for the treatment of heart failure. ARCA biopharma’s second product candidate, Gencaro (bucindolol), is a beta blocker and mild vasodilator that is in Phase III clinical development for the treatment of atrial fibrillation. ARCA biopharma Inc has a market cap of 28.53M as of 2022, a Return on Equity of -20.98%.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. The company’s market cap is 861.63M as of 2022 and its ROE is -672.28%. The company’s focus on immunology, inflammation and oncology makes it a promising candidate for investment.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for the treatment of haemophilia and other bleeding disorders. The company’s market cap as of 2022 is $42.73M and its ROE is -1.18%. Freeline’s lead product candidate, FLT190, is a long-acting recombinant factor IX therapy that is currently in Phase I/II clinical trials for the treatment of haemophilia B.
Investors in PRAXIS PRECISION MEDICINES may be encouraged by the company’s second quarter 2023 results, with total revenue increasing significantly from the same quarter last year and net income improving. Compared to the significant losses reported in the same quarter of the previous year, the company’s current financial performance may indicate further positive progress is being made. It remains to be seen whether this will continue in the quarters ahead, and investors should continue to watch PRAXIS PRECISION MEDICINES with a close eye in order to make informed investment decisions.